Navigation Links
Investigational agent targets gene signaling pathways to improve response for patients with CLL
Date:12/8/2012

erence, Consultant Hematologist and Head of the CLL Unit at The Royal Marsden NHS Foundation Trust in London. "Equally important, the exciting efficacy and safety data that we are seeing for this drug in these studies underscore the significant progress we are making in our quest to better understand and attack the specific cellular targets responsible for CLL, particularly in these vulnerable patient populations."

National Cancer Institute, "SEER Stat Fact Sheets: Chronic Lymphocytic Leukemia," http://seer.cancer.gov/statfacts/html/clyl.html (Accessed October 2012). Gribben, J.G., "How I treat CLL up front," Blood 115, no. 2 (2009): 187-197.

This press conference will take place on Saturday, December 8, at 8:00 a.m. EST

The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and is Tolerable in Treatment Nave (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in Phase Ib/II Study [Abstract 189]

New research demonstrates that a novel investigational therapeutic agent called ibrutinib may be an effective and safe targeted treatment option for previously untreated, hard-to-treat, and relapsed patients with chronic lymphocytic leukemia (CLL).

Primary treatment for CLL includes a combined chemotherapy-based regimen with fludarabine and cyclophosphamide, along with the immune therapy rituximab. While rituximab is effective, it is generally not well tolerated among elderly patients. Treatment with this drug also compromises the immune system by attacking both cancerous and normal cells, putting patients at risk for a range of infection
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6

Related medicine news :

1. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
2. Rilpivirine for HIV: Added benefit for single agent proven
3. Travel Services (MyTSOnline) in Valencia Teams Up With Vendors to Become the Number One Travel Agent in the Santa Clarita Valley
4. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
5. Scientists ID Cancer-Causing Agent in Smokeless Tobacco
6. Therapy combining exercise and neuroprotective agent shows promise for stroke victims
7. New substances 15,000 times more effective in destroying chemical warfare agents
8. Difficult to diagnose cases of infectious endocarditis solved with SPECT/CT imaging agent
9. Imaging agents predict breast cancer response to endocrine therapy
10. Pig stomach mucins are effective as anti-viral agents for consumer products
11. Method developed by VTT targets diagnosis of early Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... Physicians’ ... Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® meeting, is seeking ... 6 in New York City. The annual legacy meeting uses a variety of ...
(Date:8/31/2015)... New York, New York (PRWEB) , ... August 31, 2015 , ... ... eyes to autumn, when play-offs and the World Series will dominate the sports world. ... its division and eventually advance to the final series. For children, especially those who ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... with e-Spirit to future-proof its content management system (CMS) and make website updates ... Digital Sports in making the websites of the Bundesliga (the German equivalent of ...
(Date:8/31/2015)... , ... August 31, 2015 , ... For 12 years, ... have acknowledged September 26th as Mesothelioma Awareness Day . On this day, and ... with several ways of becoming involved and helping the cause. , “One of the ...
(Date:8/31/2015)... ... August 31, 2015 , ... Chicago-based company The Mood ... to raise money and awareness for breast and ovarian health. During September ... incandescent Mood-lite sold to Bright Pink® to encourage households, dorms, and offices around ...
Breaking Medicine News(10 mins):Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 2Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 3Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 4Health News:New Children's Baseball Series Offers Young Fans a Way to Celebrate the World Series 2Health News:On the Ball with FirstSpirit: German Soccer League (DFL Digital Sports) Opts for e-Spirit’s CMS 2Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 2Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 3Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 2Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 3
... are the oldest delivery method available, they are ... Several factors have contributed to this trend, the ... of insulin pens. (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )New analysis ... , European Insulin Delivery Devices Market , ...
... Florida orthopedic surgeon Dr. Steve Meadows is one of the few ... ... Delray Beach, FL (PRWEB) March 17, 2009 -- A breakthrough shoulder ... lost the mobility in their arm from a damaged rotator cuff, ...
... ... Newark, DE (PRWEB) March 17, 2009 ... ) have demonstrated that single embryos cultured under proper conditions ... successfully in women under age 35. In national results ...
... President of,Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) ... on Wednesday, March 18th at 10:10 AM,in the Harbor ... Philips was named President of ... was Vice President and General Manager of Bayer Healthcare ...
... costs that businesses pay to care for one premature baby ... dozen healthy, full-term infants, according to new statistics from the ... healthy full-term babies from birth through their first birthday was ... paid for by health plans, according to the new data. ...
... Inc. , the Northeast Ohio venture development organization that ... Case Technology Ventures (CTV) , a pre-seed stage ... Western Reserve University , recently announced an investment commitment ... Cleveland, OH company commercializing neurostimulation technology developed at ...
Cached Medicine News:Health News:Insulin Pens and Growing Diabetic Community Increase Market for Insulin Delivery Devices in Europe, Says Frost & Sullivan 2Health News:Insulin Pens and Growing Diabetic Community Increase Market for Insulin Delivery Devices in Europe, Says Frost & Sullivan 3Health News:Insulin Pens and Growing Diabetic Community Increase Market for Insulin Delivery Devices in Europe, Says Frost & Sullivan 4Health News:Innovative Shoulder Surgery Offers Exciting New Option for South Florida Residents with Severe Shoulder Problems 2Health News:Innovative Shoulder Surgery Offers Exciting New Option for South Florida Residents with Severe Shoulder Problems 3Health News:Innovative Shoulder Surgery Offers Exciting New Option for South Florida Residents with Severe Shoulder Problems 4Health News:Most IVF Patients Under 35 Should Have Single Embryo Transfer, According to Latest SART Data 2Health News:Most IVF Patients Under 35 Should Have Single Embryo Transfer, According to Latest SART Data 3Health News:Cell Therapeutics, Inc. (CTI) President Craig Philips to Present at Invest Northwest 2Health News:Medical costs for one premature baby could cover a dozen healthy births 2Health News:Medical costs for one premature baby could cover a dozen healthy births 3Health News:JumpStart and Case Technology Ventures Invest in Neuros Medical 2Health News:JumpStart and Case Technology Ventures Invest in Neuros Medical 3Health News:JumpStart and Case Technology Ventures Invest in Neuros Medical 4Health News:JumpStart and Case Technology Ventures Invest in Neuros Medical 5
(Date:8/31/2015)... Aug. 31, 2015  Diplomat Pharmacy, Inc. (NYSE: DPLO ... Phil Hagerman , Chairman & CEO, and Sean ... Mr. Hagerman and Mr. Whelan are scheduled ... Boston on Wednesday, September 9, 2015 ... Whelan are also scheduled to participate in the Robert W. ...
(Date:8/31/2015)... AVIV, Israel , August 31, 2015 /PRNewswire/ ... Ltd. (TASE: BOLT, OTCQX: BLGTY) ("BioLight" or ... and commercializes biomedical innovations in ophthalmology and cancer ... Micromedic Technologies (TASE: MCTC), has identified several new ... of the jawbone in patients treated with bisphosphonate ...
(Date:8/31/2015)... 31, 2015  Soligenix, Inc. (OTCQB: SNGX) ... developing products that address unmet medical needs in ... today it has completed enrollment of the additional ... (DRC) earlier this year, into the company,s Phase ... innate defense regulator (IDR) and is being evaluated ...
Breaking Medicine Technology:Diplomat to Participate in Upcoming Investor Conferences 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6
... BNVI ), a pharmaceutical company focused on the ... health and cancer, today announced that Dr. Isaac Cohen, O.M.D., ... Cowen and Company 31st Annual Healthcare Conference at 9:30 a.m. ... held at the Boston Marriott Copley Place, in Boston, Massachusetts. ...
... March 7, 2011   PDL BioPharma, Inc. (PDL) ... the first quarter ending March 31, 2011 of approximately $83 ... the first quarter of 2010, an expected 34 percent year-over-year ... million settlement received from UCB Pharma S.A. (UCB) in January ...
Cached Medicine Technology:Bionovo to Present at the Cowen and Company 31st Annual Healthcare Conference 2PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million 2PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million 3PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: